{"version":"1.0","type":"link","title":"Zanubrutinib, lenalidomide, rituximab, temozolomide ± methotrexate as first-line treatment for primary central nervous system lymphoma: A prospective, open-label, multicentre clinical trial.","author_name":"Song J 외","author_url":"https://prs-insight.online/author/Song%20J","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/159376","thumbnail_width":1200,"thumbnail_height":630}